T2 Biosystems, Inc. (TTOO)
| Market Cap | 56.09K -98.4% |
| Revenue (ttm) | 7.68M -30.2% |
| Net Income | -42.95M |
| EPS | -4.08 |
| Shares Out | 28.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35 |
| Average Volume | 7,978 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0020 |
| 52-Week Range | 0.0001 - 0.1800 |
| Beta | 1.24 |
| RSI | 53.09 |
| Earnings Date | May 13, 2026 |
About T2 Biosystems
T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts. [Read more]
Financial Performance
In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.
Financial StatementsNews
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced tha...
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream Intends to accelerate broad adoption of direct-from-...
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that...
T2 Biosystems to Host Business Update Call on October 10, 2024
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that...
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, tod...
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, tod...
T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plan...
T2 Biosystems to Attend Upcoming Investor Conferences
LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plan...
T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor
LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the e...
T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that...
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements
LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today...
T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that ...
T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that ...
T2 Biosystems Announces CRG's Conversion from Preferred Stock to Common Stock
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today...
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
Advances plan to launch T2Lyme Panel for detection of early Lyme disease Advances plan to launch T2Lyme Panel for detection of early Lyme disease
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass.
T2 Biosystems Announces First Quarter 2024 Financial Results
Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period Achieved double-digit growth in sepsis product revenue and reduced debt b...
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity
Strengthens balance sheet by reducing total debt by approximately 80% over the past year Strengthens balance sheet by reducing total debt by approximately 80% over the past year
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today tha...
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced res...
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, tod...
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes Study demonstrates T2Resistance Panel utilization enables fas...
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced tha...
T2 Biosystems (TTOO) share price stays stable post Q4 earnings
T2 Biosystems Inc. (TTOO), a prominent player in the field of medical diagnostics, recently announced its financial results for the fourth quarter of 2023, signaling a pivotal moment for the company.